Vectura Group Share Price

VEC

GB00BKM2MW97

Delayed London S.E. 16:35:22 18/10/2021 BST			5-day change	1st Jan Change
164.80 ^GBX	-.--%		-.--%	-

30/10/25	Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited	CI
16/09/24	Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million.	CI

Analysts' recommendations : Vectura Group

27/05/21	Vectura : Panmure Downgrades Vectura Group To Hold From Buy, Raises PT	MT
22/01/21	Vectura : Citigroup Downgrades Vectura To Neutral From Buy, Keeps PT	MT

More recommendations

Press Releases : Vectura Group

17/11/21	Vectura : wins Mediscience’s Best Communication Award Published17/11/2021 Read more	PU
14/09/21	Vectura : at Formulation and Delivery UK congress, London 21-22 September Published14/09/2021 Read more	PU
08/09/21	Norges Bank : - Form 8.3 - Vectura Group PLC	PR
01/09/21	Dimensional Fund Advisors Ltd. : Form 8.3 - VECTURA GROUP PLC - Ordinary Shares	AQ
24/08/21	Vectura : Our CDMO expertise in the spotlight Published24/08/2021 Read more	PU

More press releases

News in other languages : Vectura Group

16/09/21	Résumé des principales informations économiques du jeudi 16 septembre
16/09/21	Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 16 septembre 2021
16/09/21	Philip Morris : offre inconditionnelle sur Vectura Group
16/09/21	Philip Morris International : confirme le rachat de Vectura
16/09/21	USA-Les valeurs à suivre à Wall Street (actualisé)

More news

Managers and Directors : Vectura Group

Manager	Title	Age	Since
Anthony Fitzpatrick CEO	Chief Executive Officer	-	-
Geraldine Venthoye CTO	Chief Tech/Sci/R&D Officer	-	31/05/2016
Robert J Zeitler SEC	Corporate Secretary	-	29/06/2025

Director	Title	Age	Since
Chad Williams BRD	Director/Board Member	53	14/09/2023
Charles Schumacher BRD	Director/Board Member	57	29/06/2025

More insiders

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Employees

Sector

More about the company

Market Cap	1B 867M 816M 744M 1.39B 94.9B 1.4B 9.67B 3.75B 48.52B 3.77B 3.69B 159B	P/E 2019	-27.3x	P/E 2020	6.2x
Enterprise Value	930M 802M 756M 689M 1.29B 87.87B 1.3B 8.95B 3.47B 44.93B 3.49B 3.42B 148B	EV / Sales 2019	2.8x	EV / Sales 2020	3.49x
Free-Float	-	Yield 2019 *	-	Yield 2020	-

30/10/25	Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited	CI
16/09/24	Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million.	CI
16/04/24	Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	CI
28/12/21	EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	CI
03/12/21	Philip Morris CEO does not need M&A to hit smoke free goals	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION"	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION"	RE

5 years	163.4		170.4
10 years	59.1		180.88

Date	Insider	Type	Quantity	% Market Cap.
01/10/21	Paul Fry	Exercice	81,089	0.0133%
01/10/21	Paul Fry	Sell	119,429	0.0196%
01/10/21	Paul Fry	Exercice	1,928,114	0.3160%

	2019	2020
Net sales	178M 154M 145M 132M 247M 16.84B 249M 1.72B 666M 8.61B 670M 655M 28.29B	191M 164M 155M 141M 264M 18.01B 266M 1.83B 712M 9.21B 716M 700M 30.24B
Net income	-22.1M -19.07M -17.96M -16.36M -30.59M -2.09B -30.82M -213M -82.52M -1.07B -82.99M -81.17M -3.51B	122M 106M 99.47M 90.63M 169M 11.56B 171M 1.18B 457M 5.91B 460M 450M 19.42B
Net Debt	-66.5M -57.37M -54.04M -49.24M -92.04M -6.28B -92.73M -640M -248M -3.21B -250M -244M -10.55B	-74.4M -64.18M -60.46M -55.09M -103M -7.03B -104M -716M -278M -3.59B -279M -273M -11.8B

Vectura Group Share Price

Stocks

VEC

GB00BKM2MW97

Valuation : Vectura Group

Latest news : Vectura Group

Analysts' recommendations : Vectura Group

Press Releases : Vectura Group

News in other languages : Vectura Group

Price Extremes

Managers and Directors : Vectura Group

Latest insider transactions

Financials

Company Profile